Windlas Biotech Limited
NSE: WINDLAS BSE: WINDLAS
NSE
1,065.80
-18.30 (-1.69%)
Prev Close
1084.1
Open Price
1055
Volume
95,512
Today Low / High
1055 / 1119.1
52 WK Low / High
495.65 / 1198.25
Range
1,013 - 1,119
BSE
1,066.20
-18.70 (-1.72%)
Prev Close
1084.9
Open Price
1116.35
Volume
12,027
Today Low / High
1060 / 1116.4
52 WK Low / High
494.7 / 1197
Range
1,013 - 1,120
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1065.8 (target range: 1,013 - 1,119), reflecting a change of -18.3 (-1.68804%). On the BSE, it is listed at 1066.2 (target range: 1,013 - 1,120), showing a change of -18.7 (-1.72366%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
21 Apr
1,055.00
1.02%
17 Apr
1,055.00
2.76%
16 Apr
1,070.00
-0.23%
15 Apr
1,000.00
6.97%
11 Apr
926.30
4.40%
09 Apr
918.00
-2.80%
08 Apr
949.95
-2.68%
07 Apr
832.45
11.75%
04 Apr
1,030.05
-4.53%
03 Apr
1,060.55
-3.96%
02 Apr
1,037.00
1.12%
01 Apr
1,032.00
-1.56%
28 Mar
1,030.10
1.01%
27 Mar
1,030.00
1.42%
26 Mar
985.00
4.39%
25 Mar
985.50
0.43%
24 Mar
950.00
2.21%
Windlas Biotech Limited Graph
Windlas Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Windlas Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,065.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,066.20 | 1,076.86 | 969.18 - 1,184.55 |
| 1,087.52 | 870.02 - 1,305.03 | ||
| 1,098.19 | 768.73 - 1,427.64 | ||
| Bearish Scenario | 1,066.20 | 1,055.54 | 949.98 - 1,161.09 |
| 1,044.88 | 835.90 - 1,253.85 | ||
| 1,034.21 | 723.95 - 1,344.48 |
Overview of Windlas Biotech Limited
ISIN
INE0H5O01029
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
116,776
Market Cap
22,402,002,239
Last Dividend
5.5
Official Website
IPO Date
2021-08-16
DCF Diff
660.54
DCF
411
Financial Ratios Every Investor Needs
Stock Dividend of WINDLAS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-17 | September 17, 24 | 5.5 | 5.5 | 2024-09-17 | 2024-10-24 | |
| 2023-09-05 | September 05, 23 | 4 | 4 | 2023-09-05 | 2023-10-12 | |
| 2022-09-09 | September 09, 22 | 3.5 | 3.5 | 2022-09-12 | 2022-10-19 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 628.89 Cr | 400.42 Cr | 228.47 Cr | 0.3633 | 7.88 Cr | 87.94 Cr | 129.89 Cr | 58.19 Cr | 27.97 | 91.64 Cr | 0.0925 |
| 2023-03-31 | 510.58 Cr | 329.58 Cr | 181.01 Cr | 0.3545 | 8.95 Cr | 4.01 Cr | 47.92 Cr | 42.63 Cr | 19.70 | 70.19 Cr | 0.0835 |
| 2022-03-31 | 463.37 Cr | 302.82 Cr | 160.56 Cr | 0.3465 | 6.51 Cr | 4.77 Cr | 40.28 Cr | 38.09 Cr | 18.58 | 59.13 Cr | 0.0822 |
| 2021-03-31 | 426.71 Cr | 274.41 Cr | 152.31 Cr | 0.3569 | 3.61 Cr | 3.55 Cr | 43.41 Cr | 15.83 Cr | 8.69 | 36.17 Cr | 0.0371 |
| 2020-03-31 | 328.43 Cr | 274.04 Cr | 54.39 Cr | 0.1656 | 3.87 Cr | 2.42 Cr | 32.52 Cr | 16.21 Cr | 8.90 | 36.49 Cr | 0.0494 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 5.29 Cr | 626.21 Cr | 176.27 Cr | 449.9360 Cr | 3.64 Cr | -1.65 Cr | 62.19 Cr | 185.12 Cr | 0.00 Cr | 0.00 Cr | 1.64 Cr | 171.7510 Cr |
| 2023-03-31 | 3.69 Cr | 528.98 Cr | 126.70 Cr | 402.2710 Cr | 4.99 Cr | 1.31 Cr | 74.74 Cr | 122.70 Cr | 2.01 Cr | 0.00 Cr | 5.82 Cr | 121.2420 Cr |
| 2022-03-31 | 0.57 Cr | 491.01 Cr | 96.23 Cr | 394.7770 Cr | 6.64 Cr | 6.07 Cr | 58.71 Cr | 98.47 Cr | 0.73 Cr | 0.00 Cr | 2.56 Cr | 93.9860 Cr |
| 2021-03-31 | 15.93 Cr | 296.12 Cr | 97.00 Cr | 199.1190 Cr | 32.35 Cr | 16.42 Cr | 41.46 Cr | 95.67 Cr | 1.48 Cr | 0.00 Cr | 0.00 Cr | 93.4190 Cr |
| 2020-03-31 | 18.08 Cr | 338.49 Cr | 128.83 Cr | 209.6590 Cr | 28.93 Cr | 10.86 Cr | 49.32 Cr | 70.06 Cr | 0.79 Cr | 0.00 Cr | 94.00 Cr | 125.2890 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 108.9600 Cr | -92.0680 Cr | -15.2900 Cr | 71.2760 Cr | 1.6020 Cr | 5.2880 Cr | -37.6840 Cr | 58.1870 Cr | -0.3350 Cr | -8.3010 Cr | 12.5490 Cr |
| 2023-03-31 | 60.9650 Cr | -14.1100 Cr | -43.7390 Cr | -9.9250 Cr | 3.1160 Cr | 3.6860 Cr | -70.8900 Cr | 57.0390 Cr | -5.6770 Cr | -7.6280 Cr | -16.0280 Cr |
| 2022-03-31 | 9.1300 Cr | -154.5780 Cr | 130.0880 Cr | -5.6740 Cr | -15.3600 Cr | 0.5700 Cr | -14.8040 Cr | 45.5650 Cr | -25.1950 Cr | 0.0000 Cr | -17.2490 Cr |
| 2021-03-31 | 11.4540 Cr | -20.1980 Cr | 0.7760 Cr | 5.6070 Cr | -2.1480 Cr | 15.9300 Cr | -5.8470 Cr | 21.7400 Cr | 3.8850 Cr | 0.0000 Cr | 10.0700 Cr |
| 2020-03-31 | 25.0060 Cr | -14.3410 Cr | -5.4420 Cr | 9.6960 Cr | 5.2230 Cr | 18.0780 Cr | -15.3100 Cr | 24.6680 Cr | -6.7770 Cr | 0.0000 Cr | -30.2900 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 195.02 Cr | 120.83 Cr | 74.19 Cr | 0.3804 | 17.69 Cr | 15.58 Cr | 7.45 | 28.74 Cr | 0.0799 |
| 2024-09-30 | 187.00 Cr | 116.43 Cr | 70.57 Cr | 0.3774 | 16.55 Cr | 15.66 Cr | 7.49 | 27.89 Cr | 0.0837 |
| 2024-06-30 | 175.15 Cr | 143.47 Cr | 31.69 Cr | 0.1809 | 14.67 Cr | 13.48 Cr | 6.47 | 25.01 Cr | 0.0770 |
| 2024-03-31 | 171.29 Cr | 133.54 Cr | 37.75 Cr | 0.2204 | 18.47 Cr | 16.99 Cr | 8.17 | 26.45 Cr | 0.0992 |
| 2023-12-31 | 162.21 Cr | 101.64 Cr | 60.57 Cr | 0.3734 | 16.95 Cr | 15.10 Cr | 7.26 | 23.50 Cr | 0.0931 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 0.39 Cr | 214.51 Cr | 214.89 Cr | 0.00 Cr | 82.01 Cr | 517.20 Cr | 214.71 Cr | 746.89 Cr | 275.69 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 204.38 Cr | 0.00 Cr | 0.00 Cr | 204.38 Cr | 0.00 Cr | 0.00 Cr | -449.94 Cr |
| 2024-03-31 | 5.29 Cr | 199.09 Cr | 204.38 Cr | 136.28 Cr | 62.19 Cr | 431.29 Cr | 180.29 Cr | 626.21 Cr | 176.27 Cr |
| 2023-12-31 | -168.64 Cr | 337.29 Cr | 168.64 Cr | 0.00 Cr | 0.00 Cr | 168.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.15 Cr | 169.52 Cr | 170.67 Cr | 127.40 Cr | 61.09 Cr | 388.44 Cr | 162.26 Cr | 570.02 Cr | 153.86 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 13.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 16.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 15.10 Cr | 6.78 Cr | 0.00 Cr | 0.00 Cr | 6.78 Cr | 34.21 Cr | 27.43 Cr | 0.00 Cr | 6.78 Cr |
| 2023-09-30 | 14.03 Cr | 6.66 Cr | 0.00 Cr | 0.00 Cr | 6.66 Cr | 27.43 Cr | 20.77 Cr | 0.00 Cr | 6.66 Cr |
| 2023-06-30 | 12.07 Cr | 6.38 Cr | 0.00 Cr | 0.00 Cr | 6.38 Cr | 10.06 Cr | 3.69 Cr | 0.00 Cr | 6.38 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Whole-Time Director
Mr. Ashok Kumar Windlass
Gender: male
Year Born: 1950
Executive Director
Mr. Pawan Kumar Sharma
Gender: male
Year Born: 1960
Site Quality Head
Mr. Om Prakash Sule
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Ananta Narayan Panda
Gender: male
Year Born:
President of Sales & Marketing
Mr. Mohammed Aslam
Gender: male
Year Born:
MD & Executive Director
Mr. Hitesh Windlass
Gender: male
Year Born: 1977
Chief Financial Officer & Chief Executive Officer
Ms. Komal Gupta
Gender: female
Year Born:
Joint MD & Executive Director
Mr. Manoj Kumar Windlass
Gender: male
Year Born: 1978
FAQs about Windlas Biotech Limited
Who is the CEO of the company?
The CEO is Ms. Komal Gupta.
What is the current market price of the stock?
The current price is ₹1,065.80.
What is the 52-week price range?
The range is ₹495.65-1198.25.
What is the market capitalization of the company?
The market capitalization is ₹2,240.20 crores.
What is the dividend yield?
The dividend yield is 0.52%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 36.11.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Windlas Biotech Limited (ISIN: INE0H5O01029) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,240.20 crores and an average daily volume of 116,776 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.5.